Project Oncology®

O cancro colorretal metastático é difícil de gerir e tem múltiplas mutações genéticas, expressões e amplificações, tais como o lado do tumor. E, apesar dos desafios em identificar estas distinções, estas também oferecem pistas essenciais sobre qual a melhor opção de tratamento para cada doente, tal como explicam o Dr. Scott Kopetz, o Dr. Rui-Hua Xu e o Dr. Alberto Sobrero.

El cáncer colorrectal metastásico es difícil de tratar y presenta varias mutaciones genéticas, expresiones y amplificaciones, tal como la lateralidad del tumor. Y, tal como explican el Dr. Scott Kopetz, el Dr. Rui-Hua Xu y el Dr. Alberto Sobrero, aunque identificar estas distinciones puede resultar una tarea difícil, al hacerlo se averiguan pistas esenciales para decidir cuál es la mejor opción de tratamiento para cada paciente.

Please note: This activity is no longer available for continuing education credit.

The recent approval of the first immunotherapeutic agent for cutaneous squamous cell carcinoma (cSCC) is changing the way healthcare providers treat patients with inoperable cSCC. In this roundtable discussion, a cSCC survivor draws upon his experience with the cancer when surgery and chemotherapy failed him, as our multidisciplinary faculty panel focus on how to optimally select patients with cSCC for treatment with immunotherapy.

Metastatic colorectal cancer is difficult to manage and has multiple genetic mutations, expressions, and amplifications, such as tumor sidedness. And while identifying these distinctions can be challenging, they offer essential clues to which treatment option is best for each patient, as Dr. Scott Kopetz, Dr. Rui-Hua Xu, and Dr. Alberto Sobrero explain.

Improving his patients’ post-surgical experience was Dr. Suhail Kanchwala's goal when he sought to develop a new method for autologous breast reconstruction. The result of his search has brought a new technique to the field, along with an array of benefits for patients, including reduction of post-surgical pain and opioid use.

From VEGF and EGFR-targeted therapies to emerging immunotherapies, there are several treatment options available to mCRC patients…but that also means that there’s several factors you need to think about before deciding which option is best for each individual patient. Here to break everything down with Dr. Shira Johnson is Dr. Edmond Bendaly, chairman and liaison of the Cancer Committee at Marion General Hospital in Marion, Indiana.

Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Join Dr. Richard Kim of Moffitt Cancer Center as he reveals how the sidedness of a mCRC tumor affects not only the prognosis, but also the biologic you use for each individual patient.

Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Performing KRAS testing is an essential step clinicians need to take to determine which therapeutic option is best. In fact, skipping this step can actually be detrimental to patients. Here to talk about the important role of KRAS testing in metastatic colorectal cancer is Dr. Richard Kim, Medical Oncologist at Moffitt Cancer Center.

Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

There’s much to consider when it comes to determining which therapeutic option is best for your metastatic colorectal cancer patients, which is why Dr. Richard Kim is here to walk us through his thought process using this patient case review.

Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Dr. Edmond Bendaly from the Cancer Committee at Marion General Hospital in Indiana shares a patient case that stands out from the rest—and proves the importance of consistently monitoring for side effects.

Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.